Systems biology of cisplatin resistance: past, present and future

被引:664
作者
Galluzzi, L. [1 ,2 ,3 ]
Vitale, I. [4 ,5 ]
Michels, J. [1 ,3 ,6 ]
Brenner, C. [7 ,8 ]
Szabadkai, G. [9 ,10 ]
Harel-Bellan, A. [11 ,12 ,13 ]
Castedo, M. [1 ,3 ,6 ]
Kroemer, G. [1 ,2 ,3 ,6 ,14 ]
机构
[1] Inst Gustave Roussy, Villejuif, France
[2] Univ Paris 05, Sorbonne Paris Cite, Paris, France
[3] Ctr Rech Cordeliers, Equipe Labellise Ligue Natl Canc 11, Paris, France
[4] Regina Elena Inst Canc Res, Rome, Italy
[5] Natl Inst Hlth, Rome, Italy
[6] INSERM, U848, F-94805 Villejuif, France
[7] INSERM, LabEx LERMIT, UMRS 769, Chatenay Malabry, France
[8] Univ Paris 11, Fac Pharm, F-92290 Chatenay Malabry, France
[9] UCL, Dept Cell & Dev Biol, Consortium Mitochondrial Res, London, England
[10] Univ Padua, Dept Biomed Sci, Padua, Italy
[11] Univ Paris 11, Lab Epigenet & Canc, Gif Sur Yvette, France
[12] CNRS, FRE3377, Gif Sur Yvette, France
[13] CEA, Saclay, France
[14] Hop Europe Georges Pompidou, AP HP, Paris, France
来源
CELL DEATH & DISEASE | 2014年 / 5卷
基金
欧洲研究理事会;
关键词
BCL-2; carboplatin; CTR1; DNA damage response; oxaliplatin; p53; CELL LUNG-CANCER; PLATINUM-BASED CHEMOTHERAPY; MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; ADENOSINE-TRIPHOSPHATASE ATP7B; HISTONE DEACETYLASE INHIBITOR; ANTICANCER DRUG CISPLATIN; PHASE-II TRIAL; ENDOPLASMIC-RETICULUM STRESS; GENOME-WIDE ASSOCIATION; MESSENGER-RNA LEVELS;
D O I
10.1038/cddis.2013.428
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The platinum derivative cis-diamminedichloroplatinum(II), best known as cisplatin, is currently employed for the clinical management of patients affected by testicular, ovarian, head and neck, colorectal, bladder and lung cancers. For a long time, the antineoplastic effects of cisplatin have been fully ascribed to its ability to generate unrepairable DNA lesions, hence inducing either a permanent proliferative arrest known as cellular senescence or the mitochondrial pathway of apoptosis. Accumulating evidence now suggests that the cytostatic and cytotoxic activity of cisplatin involves both a nuclear and a cytoplasmic component. Despite the unresolved issues regarding its mechanism of action, the administration of cisplatin is generally associated with high rates of clinical responses. However, in the vast majority of cases, malignant cells exposed to cisplatin activate a multipronged adaptive response that renders them less susceptible to the antiproliferative and cytotoxic effects of the drug, and eventually resume proliferation. Thus, a large fraction of cisplatin-treated patients is destined to experience therapeutic failure and tumor recurrence. Throughout the last four decades great efforts have been devoted to the characterization of the molecular mechanisms whereby neoplastic cells progressively lose their sensitivity to cisplatin. The advent of high-content and high-throughput screening technologies has accelerated the discovery of cell-intrinsic and cell-extrinsic pathways that may be targeted to prevent or reverse cisplatin resistance in cancer patients. Still, the multifactorial and redundant nature of this phenomenon poses a significant barrier against the identification of effective chemosensitization strategies. Here, we discuss recent systems biology studies aimed at deconvoluting the complex circuitries that underpin cisplatin resistance, and how their findings might drive the development of rational approaches to tackle this clinically relevant problem.
引用
收藏
页码:e1257 / e1257
页数:18
相关论文
共 321 条
[1]   The expression level of the voltage-dependent anion channel controls life and death of the cell [J].
Abu-Hamad, S ;
Sivan, S ;
Shoshan-Barmatz, V .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (15) :5787-5792
[2]  
Aebi S, 1996, CANCER RES, V56, P3087
[3]   Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria [J].
Aichler, Michaela ;
Elsner, Mareike ;
Ludyga, Natalie ;
Feuchtinger, Annette ;
Zangen, Verena ;
Maier, Stefan K. ;
Balluff, Benjamin ;
Schoene, Cedrik ;
Hierber, Ludwig ;
Braselmann, Herbert ;
Meding, Stephan ;
Rauser, Sandra ;
Zischka, Hans ;
Aubele, Michaela ;
Schmitt, Manfred ;
Feith, Marcus ;
Hauck, Stefanie M. ;
Ueffing, Marius ;
Langer, Rupert ;
Kuster, Bernhard ;
Zitzelsberger, Horst ;
Hoefler, Heinz ;
Walch, Axel K. .
JOURNAL OF PATHOLOGY, 2013, 230 (04) :410-419
[4]   Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a prognostic factor in human endometrial carcinoma [J].
Aida, T ;
Takebayashi, Y ;
Shimizu, T ;
Okamura, C ;
Higasimoto, M ;
Kanzaki, A ;
Nakayama, K ;
Terada, K ;
Sugiyama, T ;
Miyazaki, K ;
Ito, K ;
Takenoshita, S ;
Yaegashi, N .
GYNECOLOGIC ONCOLOGY, 2005, 97 (01) :41-45
[5]   A high-throughput screening for mammalian cell death effectors identifies the mitochondrial phosphate carrier as a regulator of cytochrome c release [J].
Alcala, S. ;
Klee, M. ;
Fernandez, J. ;
Fleischer, A. ;
Pimental-Muinos, Fx .
ONCOGENE, 2008, 27 (01) :44-54
[6]   α6 integrin subunit mediates laminin enhancement of cisplatin-induced apoptosis in testicular tumor germ cells [J].
Andjilani, M ;
Droz, JP ;
Benahmed, M ;
Tabone, E .
INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (01) :68-81
[7]   Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275 [J].
Bangert, Annette ;
Haecker, Sabine ;
Cristofanon, Silvia ;
Debatin, Klaus-Michael ;
Fulda, Simone .
ANTI-CANCER DRUGS, 2011, 22 (06) :494-499
[8]   Validated gene targets associated with curatively treated advanced serous ovarian carcinoma [J].
Barlin, Joyce N. ;
Jelinic, Petar ;
Olvera, Narciso ;
Bogomolniy, Faina ;
Bisogna, Maria ;
Dao, Fanny ;
Barakat, Richard R. ;
Chi, Dennis S. ;
Levine, Douglas A. .
GYNECOLOGIC ONCOLOGY, 2013, 128 (03) :512-517
[9]   Frameshifts and deletions during in vitro translesion synthesis past Pt-DNA adducts by DNA polymerases β and η [J].
Bassett, E ;
Vaisman, A ;
Tropea, KA ;
McCall, CM ;
Masutani, C ;
Hanaoka, F ;
Chaney, SG .
DNA REPAIR, 2002, 1 (12) :1003-1016
[10]   Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy [J].
Bellmunt, J. ;
Paz-Ares, L. ;
Cuello, M. ;
Cecere, F. L. ;
Albiol, S. ;
Guillem, V. ;
Gallardo, E. ;
Carles, J. ;
Mendez, P. ;
de la Cruz, J. J. ;
Taron, M. ;
Rosell, R. ;
Baselga, J. .
ANNALS OF ONCOLOGY, 2007, 18 (03) :522-528